RxDoctor Payments Data

Ann Strong, MD

Gynecology · Guilford, CTNPI 1932162054

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 94.0% of the total across 66 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 11 manufacturers reported payments, led by Pfizer at 39.1% of the total. Reporting peaked in 2019 at $298 and has fallen 82.2% since, to $53 in 2025.

$1,251in general payments, 2019–2025

Across 66 payments — averaging $18.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$489
  • AbbVie$278
  • Amgen$176
  • Astellas Pharma US Inc$93
  • Sumitomo Pharma America, Inc.$54
  • Hologic Sales And Service, LLC$53
  • plus $108 from 5 others

What the payments were for

  • Food & beverage$1,17694%
  • Education$756%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,251 in reported general payments places this provider in the 70th percentile of 39 gynecology providers in Connecticut.

See all gynecology providers in Connecticut

Medicare billing

Part B allowed, 2024
$73,069
Medicare patients
278
Services billed
1,781

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ProliaDenosumab18$31,296
MyrbetriqMirabegron29$26,010
GemtesaVibegron27$22,422
EstringEstradiol34$17,865
Estradiol244$13,413
PremarinEstrogens, Conjugated25$11,750
YuvafemEstradiol31$3,532
Estradiol (Once Weekly)Estradiol27$2,268
ProgesteroneProgesterone, Micronized48$1,851
Estradiol (Twice Weekly)Estradiol12$1,768
Estradiol-Norethindrone AcetatEstradiol/Norethindrone Acet33$1,724
Risedronate Sodium17$1,691
ValacyclovirValacyclovir Hcl59$1,545
Solifenacin Succinate37$1,498
Nystatin79$1,277

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenProlia$176$31,29618 claims
PfizerEstring, Premarin$489$29,61559 claims
Astellas Pharma US IncMyrbetriq$93$26,01029 claims
Sumitomo Pharma America, Inc.Gemtesa$54$22,42227 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 39 gynecology providers in Connecticut.

Other gynecology in Guilford

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →